• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . scRNA-seq reveals persistent aberrant differentiation of nasal epithelium driven by TNFα and TGFβ in post-COVID syndrome

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Oct 28;16(1):9494.
doi: 10.1038/s41467-025-64778-0. scRNA-seq reveals persistent aberrant differentiation of nasal epithelium driven by TNFα and TGFβ in post-COVID syndrome

K D Reddy[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Y Maluje[SUP] #[/SUP][SUP] 4 [/SUP], F Ott[SUP] 4 [/SUP], R Saurabh[SUP] 4 [/SUP], A Schaaf[SUP] 2 [/SUP], A Bohnhorst[SUP] 1 2 3 [/SUP], S B Biedermann[SUP] 1 2 3 [/SUP], J Pierstorf[SUP] 1 2 [/SUP], S Winkelmann[SUP] 5 [/SUP], B Voß[SUP] 5 [/SUP], M Laudien[SUP] 5 [/SUP], T Bahmer[SUP] 5 6 7 [/SUP], J Heyckendorf[SUP] 7 8 [/SUP], F Brinkmann[SUP] 1 2 [/SUP], S Schreiber[SUP] 8 [/SUP], W Lieb[SUP] 9 [/SUP], C A Jakwerth[SUP] 10 11 [/SUP], C B Schmidt-Weber[SUP] 10 11 [/SUP], G Hansen[SUP] 12 13 14 [/SUP], E von Mutius[SUP] 11 15 16 [/SUP], K F Rabe[SUP] 6 7 [/SUP], A M Dittrich[SUP] 12 13 14 [/SUP], N Maison[SUP] 11 15 16 [/SUP], B Schaub[SUP] 11 16 17 [/SUP], M V Kopp[SUP] 18 [/SUP], H Busch[SUP] 4 [/SUP], M Weckmann[SUP] 1 2 3 [/SUP], A Fähnrich[SUP] 19 20 [/SUP]; ALLIANCE Study Group as part of the German Centre for Lung Research (DZL)



Affiliations
Abstract

Post-COVID syndrome (PCS) affects approximately 3-17% of individuals following acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and poses a potential global health burden. While improved assessment strategies are emerging, mechanistic insights and treatment options remain limited. This study investigates molecular mechanisms underlying PCS using single-cell RNA (scRNA) transcriptomics combined with in vitro validation. scRNA analysis is performed on nasal biopsies from 25 patients with moderate or severe PCS to investigate differential cell types, signalling pathways, and cell-cell communication. Air-liquid interface cultures are used to validate findings, focusing on the TNFα-TGFβ axis. Severe PCS shows reduced numbers of ciliated cells, increased immune cell infiltration, and heightened inflammatory signaling that drives TGFβ and TNFα upregulation, in the absence of a detectable viral load. These changes trigger epithelial-mesenchymal transition, basal cell expansion and a mis-stratified nasal epithelium. In vitro experiments confirm TGFβ and TNFα as causal cytokines promoting ciliated cell loss and increased basal cell abundance. These findings indicate a sustained severe PCS is not driven by ongoing viral load but by immune cell activity and chronic cytokine production. Targeting the TNFα-TGFβ axis may mitigate immune-mediated nasal tissue damage and support epithelium restoration, offering a potential therapeutic strategy for PCS.


 
Back
Top